Freenome (NASDAQ:FRNM) Receives $18.00 Average Target Price from Analysts

Freenome (NASDAQ:FRNM) has been given a consensus rating of “Moderate Buy” by the six ratings firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $18.00.

Several research analysts have recently issued reports on the company. TD Cowen initiated coverage on Freenome in a research note on Tuesday, August 18th. They issued a “buy” rating and a $17.00 price objective for the company. Weiss Ratings started coverage on Freenome in a research note on Monday, August 24th. They issued a “sell (d+)” rating on the stock. Leerink Partners initiated coverage on shares of Freenome in a research report on Friday, August 14th. They set an “outperform” rating and a $18.00 target price on the stock. Guggenheim initiated coverage on Freenome in a research note on Thursday, August 20th. They set a “buy” rating and a $21.00 price target on the stock. Finally, BTIG Research assumed coverage on Freenome in a report on Monday, August 17th. They set a “buy” rating and a $17.00 price objective for the company.

Freenome Price Performance

NASDAQ FRNM opened at $14.79 on Tuesday. Freenome has a fifty-two week low of $9.97 and a fifty-two week high of $15.09.

Freenome Company Profile

Freenome is a biotechnology company developing blood-based tests designed to detect cancer at earlier, more treatable stages. The company combines artificial intelligence with multiomics analysis, examining biological signals in blood—including genetic, immune and other molecular indicators—to identify cancer-related patterns.

Freenome’s research and development efforts have focused on noninvasive screening for colorectal cancer, with additional programs targeting other cancers. Its platform is intended to support earlier detection and may also have applications in cancer monitoring and treatment-related decision-making.

Founded in 2014 and based in California, Freenome has pursued collaborations with healthcare and biopharmaceutical organizations to advance its testing technology.